<p>在最近的三个月里，4 位分析师对 Orchestra BioMed Hldgs（纳斯达克：OBIO）分享了他们的见解，表达了从看涨到看跌的各种观点。</p>
<p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为 Orchestra BioMed Hldgs 设定了 12 个月的价格目标，显示出平均目标为 14.5 美元，最高预估为 20.00 美元，最低预估为 11.00 美元。这一上升趋势显而易见，目前的平均值较之前的 14.33 美元的平均价格目标增加了 1.19%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png"/></p>
<h2>分析师评级调查：详尽研究</h2>
<p>对金融专家如何看待 Orchestra BioMed Hldgs 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>维持</td>
<td>买入</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>超配</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 Orchestra BioMed Hldgs 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析趋势，分析师提供定性评估，从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Orchestra BioMed Hldgs 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师在价格目标的调整中提供了对 Orchestra BioMed Hldgs 未来价值的估计。比较当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
<p>为了获得关于 Orchestra BioMed Hldgs 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 Orchestra BioMed Hldgs 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>关于 Orchestra BioMed Hldgs 的所有信息</h2>
<p>Orchestra BioMed Holdings Inc 是一家生物医学创新公司，通过风险回报共享合作伙伴关系加速高影响力技术的应用。其以合作为基础的商业模式专注于与医疗器械公司建立战略合作，以推动其开发产品的商业化。公司的旗舰产品候选包括用于治疗高血压的 BackBeat 心脏神经调节疗法（CNT）和用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus AngioInfusionBalloon（SAB）。</p>
<h3>财务里程碑：Orchestra BioMed Hldgs 的历程</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，相较于同行反映出较小的规模。这可能归因于增长预期或运营能力等因素。</p>
<p><strong>收入挑战：</strong> Orchestra BioMed Hldgs 在过去 3 个月的收入增长面临困难。截至 2025 年 9 月 30 日，公司经历了约 <strong>-12.77%</strong> 的下降。这表明其收入出现了下滑。与行业同行相比，公司在健康护理行业的增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> 公司的净利润率低于行业基准，显示出在实现强劲盈利能力方面可能面临困难。净利润率为 <strong>-2419.05%</strong>，公司可能需要解决有效成本控制方面的挑战。</p>
<p><strong>股本回报率（ROE）：</strong> Orchestra BioMed Hldgs 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-94.6%</strong>，公司可能在实现最佳财务回报方面面临障碍。</p>
<p><strong>资产回报率（ROA）：</strong> Orchestra BioMed Hldgs 的 ROA 低于行业平均水平，表明在最大化资产回报方面可能面临挑战。ROA 为 <strong>-28.22%</strong>，公司可能在实现最佳财务表现方面面临障碍。</p>
<p><strong>债务管理：</strong> Orchestra BioMed Hldgs 的债务与股本比率低于行业平均水平，为 <strong>0.37</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
<h2>理解分析师评级的相关性</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成被称为股票分析师评级的内容。通常，分析师每季度评估和评级每只股票一次。</p>
<p>分析师可能会通过对增长预估、收益和收入等指标的预测来补充他们的评级，为投资者提供更全面的展望。然而，投资者应注意，分析师和任何人一样，可能会受到主观观点的影响，从而影响他们的预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

OBIO

<p>四位分析师最近对 Orchestra BioMed Hldgs（纳斯达克代码：OBIO）进行了评估，显示出看涨和看跌情绪的混合。12 个月的平均目标价格为 14.5 美元，估计范围从 11.00 美元到 20.00 美元。分析师评级包括 “增持” 和 “买入”，反映了基于市场状况的调整。该公司面临-12.77% 的收入下降和-2419.05% 的净利润率的挑战。尽管其债务与股本比率为 0.37，属于保守水平，但其财务表现指标如股本回报率（ROE）和资产回报率（ROA）低于行业平均水平，显示出潜在的盈利能力问题</p>

<p>Across the recent three months, 4 analysts have shared their insights on Orchestra BioMed Hldgs (NASDAQ: OBIO), expressing a variety of opinions spanning from bullish to bearish.</p>
<div class="lb-trans"><p>在最近的三个月里，4 位分析师对 Orchestra BioMed Hldgs（纳斯达克：OBIO）分享了他们的见解，表达了从看涨到看跌的各种观点。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Orchestra BioMed Hldgs, revealing an average target of $14.5, a high estimate of $20.00, and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 1.19% increase from the previous average price target of $14.33.</p>
<div class="lb-trans"><p>分析师为 Orchestra BioMed Hldgs 设定了 12 个月的价格目标，显示出平均目标为 14.5 美元，最高预估为 20.00 美元，最低预估为 11.00 美元。这一上升趋势显而易见，目前的平均值较之前的 14.33 美元的平均价格目标增加了 1.19%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1767992438_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析师评级调查：详尽研究</h2>
</div><p>A comprehensive examination of how financial experts perceive Orchestra BioMed Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对金融专家如何看待 Orchestra BioMed Hldgs 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>上调</td>
<td>超配</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>维持</td>
<td>买入</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>超配</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Orchestra BioMed Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Orchestra BioMed Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Orchestra BioMed Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 Orchestra BioMed Hldgs 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析趋势，分析师提供定性评估，从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Orchestra BioMed Hldgs 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师在价格目标的调整中提供了对 Orchestra BioMed Hldgs 未来价值的估计。比较当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
</div><p>For valuable insights into Orchestra BioMed Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获得关于 Orchestra BioMed Hldgs 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Orchestra BioMed Hldgs analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Orchestra BioMed Hldgs 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>All You Need to Know About Orchestra BioMed Hldgs</h2>
<div class="lb-trans"><h2>关于 Orchestra BioMed Hldgs 的所有信息</h2>
</div><p>Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings Inc 是一家生物医学创新公司，通过风险回报共享合作伙伴关系加速高影响力技术的应用。其以合作为基础的商业模式专注于与医疗器械公司建立战略合作，以推动其开发产品的商业化。公司的旗舰产品候选包括用于治疗高血压的 BackBeat 心脏神经调节疗法（CNT）和用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus AngioInfusionBalloon（SAB）。</p>
</div><h3>Financial Milestones: Orchestra BioMed Hldgs's Journey</h3>
<div class="lb-trans"><h3>财务里程碑：Orchestra BioMed Hldgs 的历程</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，相较于同行反映出较小的规模。这可能归因于增长预期或运营能力等因素。</p>
</div><p><strong>Revenue Challenges:</strong> Orchestra BioMed Hldgs's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately <strong>-12.77%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入挑战：</strong> Orchestra BioMed Hldgs 在过去 3 个月的收入增长面临困难。截至 2025 年 9 月 30 日，公司经历了约 <strong>-12.77%</strong> 的下降。这表明其收入出现了下滑。与行业同行相比，公司在健康护理行业的增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2419.05%,</strong> the company may need to address challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 公司的净利润率低于行业基准，显示出在实现强劲盈利能力方面可能面临困难。净利润率为 <strong>-2419.05%</strong>，公司可能需要解决有效成本控制方面的挑战。</p>
</div><p><strong>Return on Equity (ROE):</strong> Orchestra BioMed Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-94.6%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Orchestra BioMed Hldgs 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-94.6%</strong>，公司可能在实现最佳财务回报方面面临障碍。</p>
</div><p><strong>Return on Assets (ROA):</strong> Orchestra BioMed Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-28.22%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Orchestra BioMed Hldgs 的 ROA 低于行业平均水平，表明在最大化资产回报方面可能面临挑战。ROA 为 <strong>-28.22%</strong>，公司可能在实现最佳财务表现方面面临障碍。</p>
</div><p><strong>Debt Management:</strong> Orchestra BioMed Hldgs's debt-to-equity ratio is below the industry average at <strong>0.37</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Orchestra BioMed Hldgs 的债务与股本比率低于行业平均水平，为 <strong>0.37</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成被称为股票分析师评级的内容。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<div class="lb-trans"><p>分析师可能会通过对增长预估、收益和收入等指标的预测来补充他们的评级，为投资者提供更全面的展望。然而，投资者应注意，分析师和任何人一样，可能会受到主观观点的影响，从而影响他们的预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

评估 Orchestra BioMed Hldgs：4 位金融分析师的见解